Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies by Mina, Roberto et al.
Carfilzomib, cyclophosphamide and dexamethasone for
newly diagnosed, high-risk myeloma patients not eligible
for transplant: a pooled analysis of two studies
by Roberto Mina, Francesca Bonello, Maria Teresa Petrucci, Anna Marina Liberati, 
Concetta Conticello, Stelvio Ballanti, Pellegrino Musto, Attilio Olivieri, Giulia Benevolo, 
Andrea Capra, Milena Gilestro, Piero Galieni, Michele Cavo, Agostina Siniscalchi, 
Antonio Palumbo, Vittorio Montefusco, Gianluca Gaidano, Paola Omedé, Mario Boccadoro,
and Sara Bringhen
Haematologica 2020 [Epub ahead of print]
Citation: Roberto Mina, Francesca Bonello, Maria Teresa Petrucci, Anna Marina Liberati, 
Concetta Conticello, Stelvio Ballanti, Pellegrino Musto, Attilio Olivieri, Giulia Benevolo, Andrea Capra,
Milena Gilestro, Piero Galieni, Michele Cavo, Agostina Siniscalchi, Antonio Palumbo, 
Vittorio Montefusco, Gianluca Gaidano, Paola Omedé, Mario Boccadoro, and Sara Bringhen. 
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients 
not eligible for transplant: a pooled analysis of two studies. 
Haematologica. 2020; 105:xxx
doi:10.3324/haematol.2019.243428
Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science.
Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that
have completed a regular peer review and have been accepted for publication. E-publishing
of this PDF file has been approved by the authors. After having E-published Ahead of Print,
manuscripts will then undergo technical and English editing, typesetting, proof correction and
be presented for the authors' final approval; the final version of the manuscript will then
appear in print on a regular issue of the journal. All legal disclaimers that apply to the
journal also pertain to this production process.
 Copyright 2020 Ferrata Storti Foundation.
Published Ahead of Print on February 27, 2020, as doi:10.3324/haematol.2019.243428.
1 
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, 
high-risk myeloma patients not eligible for transplant: a pooled analysis of 
two studies 
 
Roberto Mina
1
, Francesca Bonello
1
, Maria Teresa Petrucci
2
, Anna Marina Liberati
3
, Concetta 
Conticello
4
, Stelvio Ballanti
5
, Pellegrino Musto
6
, Attilio Olivieri
7
,
 
Giulia Benevolo
8
, Andrea 
Capra
1
, Milena Gilestro
1
, Piero Galieni
9
, Michele Cavo
10
, Agostina Siniscalchi
11
, Antonio 
Palumbo
1
*, Vittorio Montefusco
12
, Gianluca Gaidano
13
, Paola Omedé
1
, Mario Boccadoro
1
, Sara 
Bringhen
1
 
 
Affiliations 
1. Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della 
Salute e della Scienza di Torino, Torino, Italy; 
2. Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University of 
Rome, Italy; 
3. Università degli Studi di Perugia, Struttura Complessa Universitaria Oncoematologia - Azienda Ospedaliera 
Santa Maria di Terni, Italy; 
4. Division of Hematology, AOU Policlinico-OVE, University of Catania, Catania, Italy; 
5. Reparto di Ematologia con TMO, Ospedale Santa Maria della Misericordia, Perugia, Italy; 
6. Regional Department of Haematology and Unit of Haematology and Stem Cell Transplantation, IRCCS-CROB, 
Referral Cancer Center of Basilicata, Rionero in Vulture (Pz), Italy; 
7. Clinica di Ematologia, Università Politecnica delle Marche, Ancona, Italy 
8. Hematology, Città della Salute e della Scienza, Turin, Italy; 
9. Division of Hematology, Ospedale “C. e G. Mazzoni”, ASUR Marche-AV5, Ascoli Piceno, Italy; 
10. "Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Bologna, Italy; 
11. UOC Ematologia, Ospedale S. Eugenio, ASLRM2, Rome, Italy; 
12. Hematology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; 
13. Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, 
Italy; 
*Currently employed at GlaxoSmithKline AG. 
 
Correspondence to: 
Dr. Sara Bringhen, MD, PhD, Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-
Universitaria Città della Salute e della Scienza di Torino, via Genova 3 - 10126 Torino, Italy. E-mail: 
sarabringhen@yahoo.com  Tel: +39 011 633 4260/4301; Fax: +39 011 633 4187.  
ORCID ID: 0000-0003-4539-6363 
 
Abstract word count = 235 
Text word count = 2526 
Number of tables/figures = 4 
Number of references = 31  
2 
Running title: KCyd in high-risk NDMM 
 
Abstract 
Despite remarkable advances in the treatment of multiple myeloma in the last decades, the 
prognosis of patients harboring high-risk cytogenetic abnormalities remains dismal as 
compared to that of standard-risk patients. Proteasome inhibitors demonstrated to partially 
ameliorate the prognosis of high-risk patients. We pooled together data from two phase I/II 
trials on transplant-ineligible patients with multiple myeloma receiving upfront carfilzomib 
cyclophosphamide and dexamethasone followed by carfilzomib maintenance. The aim of this 
analysis was to compare treatment outcomes in patients with standard- versus high-risk 
cytogenetic abnormalities detected by fluorescence in situ hybridization (FISH) analysis. High 
risk was defined by the presence of at least one chromosomal abnormality, including t(4;14), 
del17p and t(14;16). Overall, 94 patients were included in the analysis: 57 (61%) in the 
standard-risk and 37 (39%) in the high-risk group. Median follow-up was 38 months. In 
standard- vs. high-risk patients, we observed similar progression-free survival (3-year PFS: 
52% vs. 43%, respectively; p=0.50), overall survival (3-year OS: 78% vs. 73%; p=0.38), and 
overall response rate (88% vs 95%; p=0.47), with no statistical differences between the two 
groups. No difference in terms of progression-free survival was observed between patients 
with or without del17p.  
Carfilzomib, used both as induction and maintenance agent for transplant-ineligible newly 
diagnosed multiple myeloma patients, mitigated the poor prognosis carried by high-risk 
cytogenetics and resulted into similar progression-free survival and overall survival, as 
compared to standard-risk patients. 
ClinicalTrials.gov IDs: NCT01857115 (IST-CAR-561) and NCT01346787 (IST-CAR-506). 
 
 
 
Keywords: multiple myeloma, high-risk cytogenetic abnormalities, FISH, carfilzomib, 
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Article summary 
The aim of our analysis was to pool together data from two phase I/II (IST-CAR-561) and phase II 
(IST-CAR-506) studies in order to compare the efficacy of carfilzomib-based regimens for the 
treatment of newly diagnosed, transplant ineligible multiple myeloma patients with standard- vs. high-
risk cytogenetics.  
Our analysis suggested that a carfilzomib-based treatment is effective as upfront treatment for high-
risk, transplant-ineligible multiple myeloma patients. In standard- vs. high-risk patients, we observed 
similar progression-free survival (3-year PFS: 52% vs. 43%, respectively; p=0.50), overall survival (3-
year OS: 78% vs. 73%; p=0.38), and overall response rate (88% vs. 95%; p=0.47), with no statistical 
differences between the two groups. Moreover, no difference in terms of progression-free survival was 
observed between patients with or without del17p. 
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INTRODUCTION 
Multiple myeloma (MM) is a plasma cell dyscrasia with a heterogeneous prognosis ranging 
from few years to more than a decade, according to both disease-related factors (such as 
albumin and B2M levels, cytogenetic abnormalities [CA] or presence of extramedullary 
disease) and patient-related factors (age, comorbidities, frailty status).
1–3
 To date, one of the 
most powerful prognostic markers in MM is the presence of either primary (translocations) or 
secondary (deletions or amplifications) recurrent CAs detected by fluorescent in situ 
hybridization (FISH). Deletions of chromosome 17p and TP53 have been reported in 5-20% of 
MM patients according to the cut-off adopted by laboratories and have been clearly associated 
to a dismal prognosis.
4
 Another adverse CA is t(4;14), which is carried by 12 to 15% of MM 
patients and leads to the deregulation of fibroblast growth factor receptor 3 (FGFR3) and 
multiple myeloma SET domain (MMSET).
5,6
 Eventually, the occurrence of t(14;16) has been 
associated to worse progression-free survival (PFS) and overall survival (OS) in a study 
published by the Mayo clinic,
7
 although some doubts have been cast by another study by the 
Intergroupe francophone du myélome (IFM)
8
 and conflicting results have been thereafter 
reported even in patients treated in the novel agent era. The presence of at least one of these 
3 abnormalities identifies a subgroup of patients at high risk of relapse and death.
9
 
MM is mainly a disease of the elderly, with a median age at diagnosis of 69 years.
10
 Older 
patients are usually considered not eligible for high-dose chemotherapy and autologous stem-
cell transplantation; in this population, the initial therapeutic approach includes either a 
triplet proteasome inhibitor (PI)-based regimen (bortezomib-melphalan-prednisone, VMP), a 
two-drug regimen containing an immunomodulatory agent (IMiD; lenalidomide-
dexamethasone, Rd), or a combination of both a PI and an IMiD (bortezomib-lenalidomide-
dexamethasone, VRD).
11
 In the VISTA study that led to the approval of the VMP combination, 
the median PFS was 19.8 months in high-risk (HiR) patients by FISH and 23 months in 
standard-risk (SR) ones (HR:1.29).
12,13
 In the FIRST study, among patients receiving 
continuous Rd, the median PFS was 8.4 months in HiR patients vs 31.1 in SR patients.
14,15
 
Carfilzomib is a 2nd generation PI currently approved for relapsed and/or refractory (RR)MM 
patients. In the phase III ENDEAVOR trial comparing carfilzomib-dexamethasone (Kd) to 
bortezomib-dexamethasone (Vd) the PFS and OS advantage of Kd observed in the overall 
population was also retained in HiR patients (median PFS in HiR patients treated with Kd vs 
Vd: 8.8 vs 6.0 months, p=0.007).
16
 Similarly, in the phase III ASPIRE trial, the triplet 
carfilzomib-lenalidomide-dexamethasone (KRd) proved to be superior to Rd also in patients 
4 
with HiR CA (median PFS in HiR patients treated with KRd vs Rd: 23.1 vs 13.9 months, 
p=0.08).
17
 Taken together, these results suggest that carfilzomib-based regimens might at 
least partially overcome the negative impact of HiR cytogenetics in MM patients.  
We previously published the results of two phase I/II trials showing that the combination 
carfilzomib-cyclophosphamide-dexamethasone (KCyd), followed by carfilzomib maintenance, 
was effective and well tolerated in newly diagnosed (ND)MM elderly patients.
18,19
 Here we 
report the results of a pooled analysis of patient data from the two trials aiming at evaluating 
the efficacy of a carfilzomib-based therapy in SC and HiR patients. 
 
METHODS 
Study design and treatment 
We pooled together data from two phase I/II (IST-CAR-561; NCT01857115) and phase II (IST-
CAR-506; NCT01346787) studies. Both trials enrolled NDMM patients older than 65 years of 
age or younger but not eligible for autologous stem-cell transplantation (ASCT). Ethics 
committees or institutional review boards at the study sites approved both studies, which 
were done in accordance with the Declaration of Helsinki. All patients provided written 
informed consent. 
Details of study procedures have been previously published.
18–20
 Briefly, in both trials 
treatment consisted of 9 28-day cycles of KCyD followed by maintenance with single-agent 
carfilzomib until disease progression or intolerance. Carfilzomib was administered once 
weekly (70 mg/m
2
) in the IST-CAR-561 study and twice weekly (36 mg/m
2
) in the IST-CAR-
506 one. The same doses and schedules of cyclophosphamide (300 mg on days 1,8 and 15, 
orally) and dexamethasone (40 mg on days 1,8,15 and 22) were used in both studies.   
 
Endpoints 
The aim of our analysis was to compare treatment efficacy, in terms of response to therapy, 
PFS, PFS-2 and OS in patients with SR vs HiR cytogenetics receiving carfilzomib-based 
regimens.  
Cytogenetic risk was centrally assessed by FISH analysis and t(4;14), t(11;14), t(14;16), del13 
and del17p were evaluated in both studies. A 15% cut-off point was used for detection of 
translocations and a 10% cut-off point for deletions. FISH analysis was performed on CD138+ 
5 
purified plasma cells. According to the Revised International Staging System (R-ISS) criteria 
proposed by the International Myeloma Working Group (IMWG) in 2015, high cytogenetic 
risk was defined by the presence of at least one CA among del17p, t(4;14) or t(14;16).
21
 
Patients’ fitness was defined according to the IMWG frailty score
2
 and patients were classified 
as either fit, intermediate fit or unfit. 
 
Statistical analysis 
Data from the two trials were pooled together and analyzed. Comparisons between different 
patient groups were performed using Fisher’s exact test. PFS was calculated from the date of 
enrollment to the date of progression or death or the date the patient was last known to be in 
remission. PFS-2 was calculated from the date of enrollment to the date of second 
relapse/progression or death or the date the patient was last known to be in remission. OS 
was calculated from the date of enrollment to the date of death or the date the patient was last 
known to be alive.  
Time-to-event data were analyzed using the Kaplan-Meier method; survival curves were 
compared with the log-rank test. The Cox proportional hazards model was used to estimate 
the hazard ratio (HR) values and the 95% confidence intervals (CIs). All reported p-values 
were two-sided at the conventional 5% significance level. In order to account for potential 
confounders, the comparison SR versus HiR was adjusted for age, International Staging 
System (ISS), IMWG frailty score and trial (once- vs twice-weekly carfilzomib). 
Data were analyzed using R software (Version 3.5.1). 
 
RESULTS 
Among the 121 patients that were enrolled in the two trials (63 patients from IST-CAR-561 
and 58 patients from IST-CAR-506), complete cytogenetic data were available for 94 patients: 
57 patients (61%) in the SR and 37 (39%) in the HiR group according to FISH analysis; among 
the HiR ones, t(4;14) was present in 12 patients (13%), t(14;16) in 4 patients (4%) and 
del17p in 22 (23%) patients. The median percentage of plasma cells with t(4;14) was 80% 
(range, 15-99), with t(14;16) was 85% and with del17p was 34% (10-95). 
Baseline characteristics were well balanced between SR and HiR patients and are summarized 
in Table 1. Median age at enrollment was 72 years (range 60-86) for the entire population; no 
6 
significant differences in terms of age, sex, ISS stage and frailty status were observed between 
the two groups.  
Median follow-up was 38 months for the entire cohort. Ninety-two of 94 patients started the 
induction phase (1 withdrew consent and 1 was lost to follow-up before commencing 
therapy): 56/57 in the SR and 36/37 in the HiR group. Seventy patients (74%) started the 
maintenance phase: 42 (74%) in the SR and 28 (76%) in the HR group (p=1.00). The median 
duration of treatment was 16.9 months in SR patients and 14.6 months in HiR patients. 
 
Responses to therapy are shown in Table 2. No significant differences in terms of overall 
response rate (ORR) were observed between SR and HiR patients both after the induction 
phase (86% and 92% respectively, p=0.52) and overall (induction and maintenance phases; 
88% and 95% respectively, p=0.47). Also, the rate of complete response (CR) after the 
induction phase (19% vs 22%, p=0.80) and the maintenance phase (23% vs 24%, p=1) was 
similar in SR vs HiR patients. 
Median PFS was similar between SR (not reached [NR]) and HiR (27.8 months) patients (HR 
0.81, 95% CI 0.44-1.48, p=0.50); at 3-years 52% and 43% of patients were alive and free from 
progression in the two groups, respectively. Median PFS-2 was NR and 44.1 months 
respectively (HR 0.67, 95% CI 0.32-1.39, p=0.28). No significant differences were observed in 
median OS in SR and HiR patients respectively (median OS: NR vs NR, HR 0.72, 95% CI 0.34-
1.52, p=0.38), with 78% of patients in the SR and 73% in the HiR group being alive at 3 years 
from diagnosis. (Figure 1A-C). 
No significant differences in terms of median PFS, PFS-2 and OS were observed among 
patients with or without del17p (Figure 2; PFS: 35 vs 35.7 months, HR 0.92, 95% CI 0.47-
1.82, p=0.82; PFS-2: 44.1 months vs NR, HR 1.20, 95% CI 0.55-2.64, p=0.65 ; OS: 47.5 months 
vs NR, HR 1.17, 95% CI 0.52-2.62, p=0.70). When adopting a higher cut-off for del17p 
positivity (>20%), no significant PFS difference was noted between del17p-negative and -
positive patients (median, 35.7 vs 35 months).  
 
 
DISCUSSION 
7 
The aim of our analysis was to evaluate whether a carfilzomib-based upfront treatment could 
abrogate the negative impact of HiR cytogenetics and ameliorate the prognosis of transplant-
ineligible MM patients carrying HiR CAs.  
Our results showed similar ORR and CR/stringent CR rates between SR and HiR patients 
according to the cytogenetic profile, as well as no significant differences in terms of PFS, PFS-2 
and OS between the two groups. Furthermore, KCyd seemed to mitigate the poor prognosis 
conferred by del17p in terms of PFS, PFS-2 and OS. 
In Europe, Rd and VMP are currently the first-line regimens of choice for the treatment of 
older NDMM patients. To date, however, no prospective data on the comparison of VMP and 
Rd have been published, and the results of the first prospective, phase IV trial comparing 
these two standards of care are awaited (NCT03829371). However, we have recently 
published a pooled analysis of two phase III studies in which patients were treated either with 
VMP or Rd plus lenalidomide maintenance (Rd-R), showing a PFS (HR: 0.54) and OS (HR: 
0.73) advantage in HiR patients receiving bortezomib upfront.
22
 These results were in line 
with those generated in another phase III study in the transplant setting, in which bortezomib 
partially improved the poor prognosis of HiR patients carrying t(4;14) and/or del17p.
23
  
In the ASPIRE trial, the addition of carfilzomib to Rd (KRd) improved the median PFS of 
approximatively 10 months compared to Rd in patients with HiR cytogenetics, although 
median PFS in HiR patients treated with KRd (23 months) remained approximatively 6 
months shorter than in SR patients (29 months).
17
 In the ENDEAVOR trial, the doublet Kd 
proved to be superior to Vd in HiR patients (HR for PFS: 0.64, 95% CI 0.45-0.92, p=0.007), 
although median PFS was inferior in HiR vs SR patients receiving Kd (8.8 months vs NR, 
respectively).
16
 In HiR RRMM patients,  ixazomib in combination with Rd also proved to be 
effective as compared to Rd (HR 0.54, 95% CI 0.32-0.91, p=0.021), with similar median PFS in 
HiR and SR patients treated with this triplet (21.4 and 20.6 months, respectively).
24
 The 
efficacy of newer PIs in HiR patients may be even more pronounced in the upfront setting, in 
which the probability of HiR patients treated with KRd of achieving  at least a very good 
partial response (≥VGPR) or a CR was similar to that of SR patients.
25
 In the phase II FORTE 
study, similar at least VGPR rates (79% vs. 86%) and minimal residual disease negativity 
(62% vs. 49%) were obtained with 8 cycles of KRd irrespective of ASCT in both SR and HiR 
disease according to the R-ISS.
26
 These results confirmed the efficacy in HiR patients that we 
observed with carfilzomib in the non-transplant setting.  
8 
The IMWG recommends the inclusion of a PI in the upfront treatment of  HiR NDMM 
patients.
21
  Our results are in line with the evidence that PIs, especially the 2
nd
 generation 
ones such as carfilzomib, can at least partially abrogate the adverse impact of high risk CAs 
and ameliorate the prognosis of HiR patients. 
As we mentioned above, current approved treatment options in transplant-ineligible NDMM 
patients include Rd, VMP with or without daratumumab and VRD, with Dara-Rd coming soon. 
Despite the pitfalls of cross-trial comparisons, the median PFS and OS observed in HiR 
patients receiving carfilzomib-based therapy in our analysis compare favorably with those 
observed in HiR patients receiving Rd in the FIRST trial
15
 (PFS: 8.4 months; OS: 29.3 months) 
and VMP in the VISTA study
12
 (median PFS: 19.8 months), with results similar to those 
observed in HiR patients treated with Dara-Rd in the phase III MAIA study.
27
 Daratumumab, 
combined to either VMP or Rd, will represent the new standard of care in the upfront 
treatment of transplant-ineligible patients. The median PFS of patients treated with Dara-VMP 
was 36.4 months in the recently updated ALCYONE study and NR at 30 months in the MAIA 
study with Dara-Rd.
28,29
 Despite these impressive results, the PFS benefit seemed striking in 
SR patients (HR 0.39 for Dara-VMP and 0.49 for Dara-Rd), while it was less evident in HiR 
patients (HR 0.78 for Dara-VMP and 0.85 for Dara-Rd). In the era of anti-CD38-based first-line 
regimens, HiR genetic lesions are still an unfavorable prognostic factor and HiR patients 
continue to represent an unmet medical need. 
 
Our analysis has some limitations. First of all, the small number of patients analyzed does not 
allow to draw definite conclusions on this topic, but prompts further evaluation of carfilzomib 
as induction therapy in transplant-ineligible patients. We used a 10% cut-off to define the 
positivity or negativity for del17p, even though the median percentage of plasma cells with 
del17p was sensibly higher (34%, range 17-80). The exact cut-off to be used to define del17p 
positivity is a matter of controversy: while the Mayo Clinic group showed no correlation 
between PFS and OS and the mutational burden in del17p patients, a recent study published 
by Thakurta et al. showed a positive correlation between a high cancer clonal fraction and 
survival outcomes.
30,31
 Remarkably, our results remained consistent when a higher cut-off for 
del17p positivity was adopted (>20%, as in the ENDEAVOR trial). At the very time when the 
two trials included in our analysis were being designed, the impact of other HiR genetic 
features, such as bi-allelic inactivation, was still unknown, and therefore it could not be 
addressed in our work.  
9 
The prolonged use of carfilzomib in our study may have had a beneficial role in HiR patients. 
The available evidence suggests that continuous therapy could be superior to fixed duration 
therapy and could particularly benefit HiR patients. However, continuous therapy is not 
sufficient to overcome the poor prognosis of adverse CA. For instance, in the FIRST study, the 
median PFS of HiR patients treated with continuous Rd was only 9 months.
14,15
 In our 
analysis, the median duration of therapy was similar between SR and HiR patients (16.9 vs 
14.6 months), meaning that both groups of patients benefited from prolonged treatment.  
In conclusion, the results of our pooled analysis suggest that a carfilzomib-based treatment is 
effective as upfront treatment for HiR, transplant-ineligible MM patients. Carfilzomib may 
contribute to fill the gap between SR and HiR patients, thus improving the poor prognosis of 
the latter. Our results provide the basis for a further investigation of carfilzomib as upfront 
therapy for the treatment of HiR MM patients.  
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Tables 
 
Table 1. Patient characteristics at baseline 
 ALL PATIENTS 
n=94 
STANDARD-RISK PATIENTS 
n=57 
HIGH-RISK PATIENTS 
n=37 
Age 
    median (range) 
    ≥75 years n (%) 
 
72 (68-75) 
24 (26%) 
 
72 (68 -75) 
16 (28%) 
 
72 (68-74) 
8 (22%) 
Sex, n (%) 
    Male 
    Female 
 
40 (43%) 
54 (57%) 
 
24 (42%) 
33 (58%) 
 
16 (43%) 
21 (57%) 
ISS, n (%) 
    I 
    II 
    III 
 
28 (30%) 
32 (34%) 
34 (36%) 
 
19 (33%) 
17 (30%) 
21 (37%) 
 
9 (24%) 
15 (41%) 
13 (35%) 
FISH, n (%) 
    t(4;14) 
    t(14; 16) 
    del17p 
≥2 CA* 
 
12 (13%) 
4 (4%) 
22 (23%) 
1 (1%) 
 
- 
- 
- 
- 
 
12 (32%) 
4 (11%) 
22 (59%) 
1 (3%) 
 FRAILTY SCORE, n (%) 
    Fit 
    Intermediate  
    Frail 
 
53 (56%) 
29 (31%) 
12 (13%) 
 
34 (60%) 
18 (32%) 
5 (9%) 
 
19 (51%) 
11 (30%) 
7 (19%) 
LDH [UI/mmol] 
    median (range) 
    Missing 
 
282.5 (168-361) 
18 (19%) 
 
288 (198-359) 
13 (23%) 
 
274 (154-386) 
5 (14%) 
Abbreviations: ISS, International Staging System; FISH, fluorescence in situ hybridization; LDH, lactate 
dehydrogenase; n, number; CA, cytogenetic abnormalities. 
*At least 2 cytogenetic abnormalities among t(4;14), t(14;16) and del17p.  
13 
Table 2.  Best response after induction phase and overall (induction and maintenance).  
 ALL PATIENTS 
n=94 
STANDARD-RISK PATIENTS 
n=57 
HIGH-RISK PATIENTS 
n=37 
RESPONSE AFTER INDUCTION 
ORR, n (%) 
sCR/CR 
VGPR 
PR 
SD  
NA 
83 (88%) 
19 (20%) 
42 (45%) 
22 (23%) 
6 (6%) 
5 (5%) 
49 (86%) 
11 (19%) 
25 (44%) 
13 (23%) 
4 (7%) 
4 (7%) 
34 (92%) 
8 (22%) 
17 (46%) 
9 (24%) 
2 (5%) 
1 (3%) 
RESPONSE INDUCTION and MAINTENANCE 
ORR, n (%) 
sCR/CR 
VGPR 
PR 
SD  
NA 
85 (90%) 
22 (23%) 
42 (45%) 
21 (22%) 
4 (4%) 
5 (5%) 
50 (88%) 
13 (23%) 
25 (44%) 
12 (21%) 
3 (5%) 
4 (7%) 
35 (95%) 
9 (24%) 
17 (46%) 
9 (24%) 
1 (3%) 
1 (3%) 
Abbreviations: ORR, overall response rate; CR, complete response; sCR, stringent CR; VGPR, very good partial 
response; PR, partial response; SD, stable disease; NA, not available; n, number. 
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Figure titles 
 
 
Figure 1. Standard-risk vs high-risk patients. Panel A, progression free survival (PFS); Panel 
B, PFS-2; Panel C, overall survival (OS)  
 
 
 
Figure 2. Median progression-free survival (PFS) according to del17p status 
 


